Suppr超能文献

人纤溶酶原激活剂尿激酶55,000道尔顿形式的细胞结合位点。

A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

作者信息

Vassalli J D, Baccino D, Belin D

出版信息

J Cell Biol. 1985 Jan;100(1):86-92. doi: 10.1083/jcb.100.1.86.

Abstract

The secretion of plasminogen activators has been implicated in the controlled extracellular proteolysis that accompanies cell migration and tissue remodeling. We found that the human plasminogen activator urokinase (Uk) (Mr 55,000 form) binds rapidly, specifically, and with high affinity to fresh human blood monocytes and to cells of the monocyte line U937. Upon binding Mr 55,000 Uk was observed to confer high plasminogen activator activity to the cells. Binding of the enzyme did not require a functional catalytic site (located on the B chain of the protein) but did require the noncatalytic A chain of Mr 55,000 Uk, since Mr 33,000 Uk did not bind. These results demonstrate the presence of a membrane receptor for Uk on monocytes and show a hitherto unknown function for the A chain of Uk: binding of secreted enzyme to its receptor results in Uk acting as a membrane protease. This localizes plasminogen activation near the cell surface, an optimal site to facilitate cell migration.

摘要

纤溶酶原激活剂的分泌与伴随细胞迁移和组织重塑的可控细胞外蛋白水解有关。我们发现人纤溶酶原激活剂尿激酶(Uk)(55,000分子量形式)能快速、特异性且高亲和力地结合新鲜人血单核细胞及单核细胞系U937的细胞。结合后,观察到55,000分子量的Uk赋予细胞高纤溶酶原激活剂活性。该酶的结合不需要功能性催化位点(位于蛋白的B链上),但确实需要55,000分子量Uk的非催化A链,因为33,000分子量的Uk不结合。这些结果证明单核细胞上存在Uk的膜受体,并揭示了Uk的A链迄今未知的功能:分泌的酶与其受体结合导致Uk作为膜蛋白酶起作用。这将纤溶酶原激活定位在细胞表面附近,这是促进细胞迁移的最佳位点。

相似文献

1
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.
J Cell Biol. 1985 Jan;100(1):86-92. doi: 10.1083/jcb.100.1.86.
4
Characterization of the high-affinity interaction between human plasminogen and pro-urokinase.
Eur J Biochem. 1985 Jul 1;150(1):141-4. doi: 10.1111/j.1432-1033.1985.tb08999.x.
7
The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
Exp Cell Res. 1994 Oct;214(2):486-98. doi: 10.1006/excr.1994.1286.
10
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
Proc Natl Acad Sci U S A. 1989 Jul;86(13):4828-32. doi: 10.1073/pnas.86.13.4828.

引用本文的文献

2
CD87-targeted BiTE and CAR-T cells potently inhibit invasive nonfunctional pituitary adenomas.
Sci China Life Sci. 2024 Oct;67(10):2169-2185. doi: 10.1007/s11427-024-2591-7. Epub 2024 Jul 8.
4
Endothelial-specific Enhancer as a Cis Element of Regulation by TNF-alpha, IL-1beta, and VEGF.
Curr Pharm Des. 2024;30(21):1630-1640. doi: 10.2174/0113816128296376240424072322.
5
6
Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.
Front Cell Dev Biol. 2022 Apr 8;10:818616. doi: 10.3389/fcell.2022.818616. eCollection 2022.
7
The uPA System Differentially Alters Fibroblast Fate and Profibrotic Ability in Skin Fibrosis.
Front Immunol. 2022 Mar 16;13:845956. doi: 10.3389/fimmu.2022.845956. eCollection 2022.
8
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.
J Transl Med. 2022 Mar 18;20(1):135. doi: 10.1186/s12967-022-03329-3.
9
Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.
Cancers (Basel). 2022 Jan 19;14(3):498. doi: 10.3390/cancers14030498.
10

本文引用的文献

2
Evidence for membrane association of plasminogen activator activity in mouse macrophages.
Biochem Biophys Res Commun. 1980 May 30;94(2):480-6. doi: 10.1016/0006-291x(80)91256-5.
5
Structural relationship between human high and low molecular mass urokinase.
Hoppe Seylers Z Physiol Chem. 1982 Feb;363(2):133-41. doi: 10.1515/bchm2.1982.363.1.133.
7
Transforming growth factor(s) production enables cells to grow in the absence of serum: an autocrine system.
Proc Natl Acad Sci U S A. 1982 Jan;79(2):485-9. doi: 10.1073/pnas.79.2.485.
10
Chemotactic response of monocytes to thrombin.
J Cell Biol. 1983 Jan;96(1):282-5. doi: 10.1083/jcb.96.1.282.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验